menu
    • menu
    [{"orgOrder":0,"company":"XOMA","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Faricimab","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"XOMA \/ Blue Owl Capital","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Blue Owl Capital"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Gemcitabine HCl","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Ersodetug","moa":"Insulin allosteric site receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rezolute"},{"orgOrder":0,"company":"XOMA","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Mezagitamab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"XOMA","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"PTH1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"XOMA \/ Amolyt Pharma"},{"orgOrder":0,"company":"XOMA","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Chiesi Group"},{"orgOrder":0,"company":"XOMA","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Cetrelimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Janssen Biotech","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Janssen Biotech"},{"orgOrder":0,"company":"XOMA","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XOMA \/ Zydus Lifesciences","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Zydus Lifesciences"},{"orgOrder":0,"company":"XOMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Inapplicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Viracta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Viracta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Viracta Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by XOMA

    Menu

    XOMA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Viracta Therapeutics

                            Deal Size : $108.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Receives $8.1 Million Milestone for Day One Biopharmaceuticals’ Priority Voucher

                            Details : XOMA acquired potential milestones associated with Ojemda (tovorafenib), approved for patients 6 months age and older with relapsed or refractory pediatric low-grade glioma with BRAF V600 mutation.

                            Product Name : Ojemda

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 06, 2024

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Viracta Therapeutics

                            Deal Size : $108.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $54.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns $9 Million Milestone As FDA Approves OJEMDATM for pLGG

                            Details : XOMA acquired mid-single digit royalties related to Ojemda (tovorafenib), approved for treating patients aged 6 months and older with r/r pediatric low-grade glioma harboring BRAF V600 mutation.

                            Product Name : Ojemda

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 25, 2024

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $54.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Faricimab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Blue Owl Capital

                            Deal Size : $140.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital ...

                            Details : Vabysmo (faricimab-svoa) is the first bispecific antibody which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising Ang-2 and VEGF-A. It is being investigated for the treatment of retin...

                            Product Name : Vabysmo

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : Faricimab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Blue Owl Capital

                            Deal Size : $140.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $59.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns $5 Million Milestone upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive P...

                            Details : Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatr...

                            Product Name : Ojemda

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $59.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-40XX

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Amolyt Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

                            Details : Amolyt will advance pre-clinical development of AZP-40XX, an anti-PTHR1 monoclonal antibody, as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).

                            Product Name : AZP-40XX

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : AZP-40XX

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Amolyt Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NIS793,Gemcitabine,Spartalizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Granted Orphan Drug Designation XOMA’s Licensed anti-TGFβ Asset NIS793

                            Details : NIS793 is a potential first in class novel antibody specific for Transforming Growth Factor Beta (TGFβ). NIS793 is an investigational compound.

                            Product Name : NIS793

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 28, 2021

                            Lead Product(s) : NIS793,Gemcitabine,Spartalizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NIS793,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $517.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pa...

                            Details : The Phase 3 trial will assess the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. The milestone payment is a part of an agreement signed between Xoma and Novartis.

                            Product Name : NIS793

                            Product Type : Antibody

                            Upfront Cash : $37.0 million

                            April 11, 2021

                            Lead Product(s) : NIS793,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $517.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrelimab,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Janssen Biotech

                            Deal Size : $0.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

                            Details : XOMA Corporation has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. Cetrelimab is the second molecule to advance to P...

                            Product Name : JNJ-63723283

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 05, 2021

                            Lead Product(s) : Cetrelimab,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Janssen Biotech

                            Deal Size : $0.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mezagitamab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $18.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development

                            Details : Xoma has earned a $2 million milestone payment from Takeda upon dosing first patient in its Phase 2 safety, tolerability, and efficacy study of mezagitamab (TAK-079) in generalized myasthenia gravis. Xoma may receive up to $16 M in additional millstone.

                            Product Name : TAK-079

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            November 16, 2020

                            Lead Product(s) : Mezagitamab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $18.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NIS793,Gemcitabine,Spartalizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $517.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pa...

                            Details : The Phase 2 trial will assess the efficacy and safety of NIS793 in first-line metastatic pancreatic ductal adenocarcinoma. The milestone payment is apart of an agreement signed between Xoma and Novartis.

                            Product Name : NIS793

                            Product Type : Antibody

                            Upfront Cash : $37.0 million

                            October 28, 2020

                            Lead Product(s) : NIS793,Gemcitabine,Spartalizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $517.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth